AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to | NYU Langone Health

Go Back to All Clinical Trials

AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
B-all
Age: Between 1 years - 30 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories: ?Isolated bone marrow relapse ?Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse. 2) Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes.

You may not be eligible for this study if the following are true:

1) Patients with B-lymphoblastic lymphoma (B-LLy). 2) Patients with Burkitt Leukemia/Lymphoma or mature B-cell leukemia. 3) Patients with Philadelphia chromosome positive (Ph+) B-ALL. 4) Patients with mixed phenotype acute leukemia (MPAL).